An Evaluation of the Australian Rotavirus Surveillance Program
DOI:
https://doi.org/10.33321/cdi.2008.32.33Keywords:
evaluation, rotavirus, vaccinationAbstract
The Australian Rotavirus Serotyping Program (ARSP) serotypes rotavirus isolates obtained from stool samples sent from Australian laboratories. In collaboration with ARSP, the Australian Government Department of Health and Ageing evaluated the program for its utility and capacity to monitor effectiveness of the rotavirus vaccines recently introduced into the Australian National Immunisation Program. The system was described using ARSP annual reports and staff interviews. The attributes of the system were assessed by adapting standard guidelines for evaluating a surveillance system. Email surveys or face to face interviews were conducted with staff of ARSP, participating laboratories, rotavirus vaccine manufacturing companies and representatives of the Communicable Diseases Network Australia. The ability of the ARSP to monitor changes in rotavirus serotype epidemiology was assessed. ARSP serotypes rotavirus isolates received from participating laboratories at least bi-annually, with results being reported at least as often. Serotype analyses have informed formulation of rotavirus vaccines and contributed to forecasting the extent of outbreaks caused by novel serotypes. The ARSP will be able to monitor changes in rotavirus serotype epidemiology and identify probable vaccination failures. Enhancement of the representativeness and sensitivity of the system are needed for the data to remain useful in the public health context. Methods for transferring data between the program and state and territory health departments need to be developed. Commun Dis Intell 2008;32:326–332.
Downloads
References
Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006;12:304–306.
Carlin JB, Jackson T, Bishop RF, Barnes GL. Cost effectiveness of rotavirus vaccination in Australia. Aust N Z J Public Health 1999;23:611–616.
Villa S, Guiscafre H, Martinez H, Munoz O, Gutierrez G. Seasonal diarrhoeal mortality among Mexican children. Bull World Health Organization 1999;77:375–380.
Kirkwood C, Bogdanovic-Sakran N, Barnes G, Bishop R. Rotavirus serotype G9P[8] and acute gastroenteritis outbreak in children, Northern Australia. Emerg Infect Dis 2004;10:1593–1600.
Gentsch J, Liard AR, Biefelt B, Griffin DD, Banyai K, Ramachandran M, et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis 2005;192 Suppl 1:S146–S159.
Galati JC, Harsley S, Richmond P, Carlin JB. The burden of rotavirus-related illness among young children on the Australian health care system. Aust N Z J Public Health 2006;30:416–421.
Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New Engl J Med 2006;354:23–33.
Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11–22.
German RR, Lee LM, Horan JM, Milstein RL, Pertowski CA, Waller MN: Guidelines Working Group Centers for Disease Control and Prevention. Updated guidelines for evaluating public health surveillance systems: recommendations from the Guidelines Working Group. MMWR Recomm Rep 2001;50(RR-13):1–35; quiz CE1–7.
Kirkwood CD, Cannan D, Bogdanovic-Sakran N, Bishop RF, Barnes GL. National Rotavirus Surveillance Program annual report 2005–06. Commun Dis Intell 2006;30:434–438.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2008 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
